Full-Time

Global Sales Performance Facilitator

Confirmed live in the last 24 hours

RELX

RELX

1,001-5,000 employees

Provides analytics and decision tools for professionals

Data & Analytics
Social Impact
Legal

Expert

Company Historically Provides H1B Sponsorship

Remote in USA

The position requires travel throughout the North America region on a regular basis (~50%) to deliver trainings.

Category
Customer Success Management
Sales & Account Management
Required Skills
Sales

You match the following RELX's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree
  • 10+ years of demonstrated successful sales experience across sales, sales enablement, and/or, sales training
  • Familiarity with various sales methodologies and processes such as Challenger, MEDDIC, Solution Selling, Consultative Selling, Value-Based Selling, and others
  • Excellent facilitation and presentation skills
  • Instructional design skills and experience developing training curricula
  • Strong leadership, collaboration and teambuilding skills
Responsibilities
  • Facilitate engaging and effective sales training in face-to-face and digital classroom settings, including both advancing skills of existing sales community and onboarding new starters in our Global Sales Methodology, The LN Way.
  • Help develop a blended learning curriculum that drives adoption of The LN Way and helps sales performers recognize relevance to their role, business and market.
  • Provide ongoing guidance and facilitation support to front-line managers and their sales teams following training sessions to ensure sustained behavior change and successful implementation of The LN Way principles.
  • Contribute subject matter expertise to project teams seeking to systemize the sales methodology training into existing workflow processes, ensuring seamless integration and practical application in day-to-day sales activities.
  • Collaborate with cross-functional teams, including sales leadership, product, marketing and sales enablement to ensure The LN Way is embedded into all activity.
  • Monitor and evaluate the effectiveness of the methodology adoption. Regularly conduct training needs analysis with stakeholder communities to identify, isolate and navigate blockers to adoption.
  • Apply change management principles and techniques to facilitate the successful adoption of the The LN Way within our sales organization.
  • Incorporate adult learning psychology and instructional design principles into curriculum design and delivery to ensure learner experience is optimal and learning leads to measurable behavior change and ROI.

RELX provides information-based analytics and decision tools tailored for professional and business customers across various sectors. The company operates in four key areas: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products utilize extensive data and analytics to assist clients, such as researchers, healthcare professionals, legal practitioners, and business executives, in making informed decisions and enhancing productivity. RELX distinguishes itself from competitors through its subscription-based business model, which ensures a consistent revenue stream, alongside income from transactional sales and advertising. The company's goal is to support corporate responsibility initiatives, focusing on diversity, social justice, and sustainable development, while actively contributing to the United Nations' Sustainable Development Goals (SDGs) through its offerings.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1894

Simplify Jobs

Simplify's Take

What believers are saying

  • LexisNexis Health Intelligence is innovating to streamline life insurance underwriting processes.
  • Enamine's database integration into Reaxys accelerates drug discovery significantly.
  • AI-driven analytics enhance efficiency in legal research tools for professionals.

What critics are saying

  • Increased competition in digital health data may impact RELX's market share.
  • Open-access publishing models threaten Elsevier's subscription-based revenue streams.
  • Data privacy regulations like GDPR may increase compliance costs for RELX.

What makes RELX unique

  • RELX's subscription model ensures a steady stream of recurring revenue.
  • The company supports UN Sustainable Development Goals through its products and partnerships.
  • RELX's diverse client base spans researchers, healthcare professionals, and legal practitioners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

PR Newswire
Feb 20th, 2025
Lexisnexis Health Intelligence Paves A Path Of Innovation To Help U.S. Life Insurers Improve The Underwriting Process

Digital Health Data Insights are Needed at Scale for Life Insurers to Continue to Reach UnderservedMarkets, Close the Life Insurance Gap and Reduce Mortality SlippageATLANTA, Feb. 20, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions today announced continued innovation of LexisNexis® Health Intelligence, its digital health data platform for the U.S. life insurance industry. The platform provides information and insights, including a concise and simplified clinical history report; leverages advanced linking, parsing and normalization; and helps life insurers scale their use of electronic health records (EHRs). These new innovations empower life insurance carriers with access to digital health data, sourced from EHRs, and advanced analytics that enable faster, more friction-free interactions for life insurance applicants, helping to streamline the underwriting workflow.Deriving insights from digital health data is critical to address life insurers' needs for future transformation and to achieve their objectives to close the coverage gap for un- or under-insured individuals, while minimizing mortality slippage and delivering a simplified buying experience. When LexisNexis Risk Solutions acquired the Human API Health Intelligence platform, it included a robust network of health data sources, a consumer consent management experience, as well as capabilities to ensure a consistent deliverable for life insurers that use EHRs in the underwriting process

PR Newswire
Jan 29th, 2025
Lexisnexis Risk Solutions Launches Research-Ready Healthcare Data Blends To Expedite Research

Blended, patient-level datasets leveraging proprietary tokenization technology simplify data enrichment while adhering to privacy standards. ATLANTA, Jan. 29, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions, a leading provider of healthcare analytics and insights, today announced the launch of new research-ready, real-world datasets designed to accelerate research timelines, reduce costs and enable more equitable analyses. Using referential-based tokenization, the patient-level datasets are blended, expert determined and certified ensuring they are standardized and research ready. This process gives research teams a more simplified way to enrich their datasets or define a cohort of interest to support specific study objectives, including benchmarking with comparator cohorts. These datasets integrate into clinical research workflows, generating impactful real-world evidence to accelerate innovation and speed-to-market

PharmiWeb
Jan 14th, 2025
Elsevier Appoints Stuart Whayman As President Of Corporate Markets

Mr. Whayman’s previous leadership roles at the company include serving as Chief Financial Officer, Chief Commercial Officer and Managing Director of the Researchers and Librarians business segmentLondon, January 14, 2025. Elsevier, a global leader in scientific information and analytics, announced today the appointment of Stuart Whayman as President of Corporate Markets effective January 6, 2025. Mr. Whayman will report to Kumsal Bayazit, CEO of Elsevier, and will lead the global business that provides advanced scientific and technical information, data and decision support solutions for innovation to R&D-focused organizations across various industries, including pharmaceuticals and chemicals.Mr. Whayman joined Elsevier in 2014, initially as Chief Financial Officer and later served as Chief Commercial Officer

ACN Newswire
Dec 5th, 2024
Shaping Airports For Tomorrow: The 8Th Edition Of Inter Airport Southeast Asia Returns To Singapore In 2025

SINGAPORE, Dec 5, 2024 - (ACN Newswire) - inter airport Southeast Asia, the premier trade exhibition and conference for airport innovation and technology in Asia, will return to Singapore from 25 to 27 March 2025 at the Marina Bay Sands. The 8th edition is expected to bring together over 3,500 representatives of the aviation industry in Asia, influencers in the airports and airlines community, and 150+ exhibitors, including world-class solution providers and airport equipment suppliers, to connect, find synergies, build partnerships, and innovate. As the aviation industry advances and new airport projects and investments surge globally, groundbreaking innovations are essential to drive its transformation. Themed “Airport Operations for Tomorrow” conversations at the exhibition and conference will highlight innovation, technology, and sustainable solutions to optimise terminal and ramp operations of the future. Asia driving majority in airport projects

PharmiWeb
Dec 4th, 2024
Elsevier Adds 43 Million Enamine Make-On-Demand Compounds To Reaxys To Accelerate Chemistry R&D

Access to Enamine’s novel compounds will allow Reaxys users to cut development times and costs by up to 90%​. ​​London, 3 December​ ​2024​ – Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine’s database of over 43 million make-on-demand (MADE) analog compounds into Reaxys. The integration will provide chemists with unparalleled access to a diverse array of chemical compounds for accelerated drug discovery and materials science research. Reaxys is a leading chemical database that combines over a billion chemistry data points from scientific journals and patents with AI to support innovation in drug discovery, chemical RD and academia. This new integration combines Enamine's expertise in compound synthesis with the comprehensive capabilities of the Reaxys platform, enabling researchers to access a vast repository of chemical information and facilitating the identification of novel drug targets, biomarkers, and screening compounds